Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients
Authors:
- 2 March 2017
- journal article
- research article
- Published by Wiley in European Journal of Cancer Care
- Vol. 27 (1) , e12666
Abstract
Depression might be associated with shorter disease specific survival. Selective serotonin reuptake inhibitors (SSRIs) were previously reported to increase the risk of certain malignancies. We aimed to evaluate the impact of SSRIs on cancer mortality. Five retrospective cohort studies were conducted in a UK population-representative database that included all individuals with an incident diagnosis of melanoma, breast, prostate lung and colorectal cancer. The primary exposure of interest was continuous use of SSRIs with past use as the comparison reference. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI). The study included 5,591 newly diagnosed cancer patients. Continuous SSRI use was associated with lower survival compared to past users for melanoma, breast, prostate, lung and colorectal cancers with HRs for the risk of death of 2.02 (95% CI 1.24–3.28), 1.91 (95% CI 1.53–2.38), 1.79 (95% CI 1.38–2.33), 1.44 (95% CI 1.19–1.75) and 1.51 (95% CI 1.21–1.72) respectively. The incidence of death during the first 2 years following cancer diagnosis associated with continuous SSRI use were elevated for breast (1.72, 95% CI 1.30–2.27), prostate (1.64, 95% CI 1.20–2.24) and lung cancers (1.45, 95% CI 1.26–1.66). In conclusion, continuous use of SSRIs might be associated with lower survival in cancer patients.Keywords
Funding Information
- National Center for Research Resources
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1TR000003, CA187185)
This publication has 37 references indexed in Scilit:
- Anti-depressant therapy and cancer risk: A nested case-control studyEuropean Neuropsychopharmacology, 2015
- Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast CancerFrontiers in Oncology, 2012
- Selective Serotonin Reuptake Inhibitors, Glioblastoma Multiforme, and Impact on Toxicities and Overall SurvivalAmerican Journal of Clinical Oncology, 2011
- Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary AnalysisJournal of Clinical Oncology, 2011
- Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitroEuropean Neuropsychopharmacology, 2009
- Depression and anxiety in women with early breast cancer: five year observational cohort studyBMJ, 2005
- Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology GroupJournal of Clinical Oncology, 2003
- Antidepressant Medication Use and Breast Cancer RiskAmerican Journal of Epidemiology, 2000
- The Read clinical classification.BMJ, 1990
- The Prevalence of Psychiatric Disorders Among Cancer PatientsJAMA, 1983